Difference between revisions of "Rizzo Lab Research"
Stonybrook (talk | contribs) (→HIV/AIDS) |
Stonybrook (talk | contribs) (→GP41) |
||
| Line 5: | Line 5: | ||
| + | {| border="1" cellpadding="8" cellspacing="0" style="background:white; text-align:left; width:90%" | ||
| + | |- style="background:white" | ||
| + | ! style="width:80%" | | ||
viral membrane fusion inhibitor development. | viral membrane fusion inhibitor development. | ||
| Line 13: | Line 16: | ||
McGillick, B. E.; Balius, T.E.; Mukherjee, S.; Rizzo, R. C. Origins of Resistance to the HIVgp41 Viral Entry Inhibitor T20. Biochemistry, 2010, 49 (17), 3575-3592 doi:10.1021/bi901915g PMID: 20230061 [http://pubs.acs.org/doi/abs/10.1021/bi901915g WEB] [http://rizzo.ams.sunysb.edu/~rizzo/StonyBrook/publications/rizzo020.pdf PDF] | McGillick, B. E.; Balius, T.E.; Mukherjee, S.; Rizzo, R. C. Origins of Resistance to the HIVgp41 Viral Entry Inhibitor T20. Biochemistry, 2010, 49 (17), 3575-3592 doi:10.1021/bi901915g PMID: 20230061 [http://pubs.acs.org/doi/abs/10.1021/bi901915g WEB] [http://rizzo.ams.sunysb.edu/~rizzo/StonyBrook/publications/rizzo020.pdf PDF] | ||
| − | + | ! style="width:20%"| http://ringo.ams.sunysb.edu/index.php/Main_Page | |
| − | | | ||
| − | |||
| − | |||
|- | |- | ||
|} | |} | ||
Revision as of 08:08, 3 February 2012
PLEASE NOTE THIS PAGE IS BEING UPDATED
Contents
HIV/AIDS
GP41
|
viral membrane fusion inhibitor development. See the following papers. Strockbine, B.; Rizzo, R. C. Binding of Anti-Fusion Peptides with HIVgp41 from Molecular Dynamics Simulations: Quantitative Correlation with Experiment. Proteins: Struct. Func. Bioinformatics, 2007, 67, 630-642. PDF McGillick, B. E.; Balius, T.E.; Mukherjee, S.; Rizzo, R. C. Origins of Resistance to the HIVgp41 Viral Entry Inhibitor T20. Biochemistry, 2010, 49 (17), 3575-3592 doi:10.1021/bi901915g PMID: 20230061 WEB PDF |
http://ringo.ams.sunysb.edu/index.php/Main_Page |
|---|
Cancer
EGFR and ErbB family
Epidermal Growth Factor Receptor (EGFR) is a drug target for treating several types of Cancers, Including Lung and breast cansers. We are instested in targeting the Tyrosine kinase domain.
See the following paper:
Balius, T. E.; Rizzo, R. C. Quantitative Prediction of Fold Resistance for Inhibitors of EGFR. Biochemistry, 2009, 48, 8435-8448. WEB PDF
MMPs
See the following paper:
Carrascal, N.; Rizzo, R. C. Calculation of Binding Free Energies for Non-zinc Chelating Pyrimidine Dicarboxamide Inhibitors with MMP-13. Bioorg. Med. Chem. Lett., 2009, 19, 47-50. PDF
Influenza
Neuraminidase
Chachra, R.; Rizzo, R. C. Origins of Resistance Conferred by the R292K Neuraminidase Mutation via Molecular Dynamics and Free Energy Calculations. J. Chem. Theory Comput., 2008 ,4, 1526-1540. PDF
Method development
DOCK development
The Rizzo Group co-develops the DOCK program [1] and contributed to the latest to releases:
The release v6.4, greatly improved the sampling behavior with the inclusion of internal energy during growth and minimization. See release notes
The release v6.5 includes a new scoring function termed Footprint similarity score. See release notes
docking testset development
To facilitate the improvements to the DOCK codebase and docking protocols, our group has developed a docking testset for pose reproduction.
See Mukherjee, S.; Balius, T.E.; Rizzo, R. C. Docking Validation Resources: Protein Family and Ligand Flexibility Experiments. J. Chem. Inf. Model, 2010, 50, 1986-2000. PDF
To obtain the testset visit Rizzo_Lab_Downloads.
docking scoring functions
Footprint similarity score is described in
Balius, T.E.; Mukherjee, S.; Rizzo, R. C. Implementation and Evaluation of a Docking-Rescoring Method Using Molecular Footprint Comparisons. J. Comput. Chem., 2011, 32, 2273-2289. PDF
